Herold Advisors, Inc. Cel Sci Corp Transaction History

Herold Advisors, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 15, 2022	SELL	$2.58 - $4.99 $3,870 - $7,485	-1,500 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$3.93 - $7.7 $5,895 - $11,550	1,500 New	1,500 $5,000
Q4 2021 Jan 20, 2022	SELL	$7.1 - $12.82 $10,650 - $19,230	-1,500 Closed	0 $0
Q3 2021 Nov 03, 2021	BUY	$7.64 - $12.49 $11,460 - $18,735	1,500 New	1,500 $16,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Herold Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Herold Advisors, Inc. with notifications on news.